Arzoxifene in breast cancer

European Journal of Cancer

Volumn 38, Issue SUPPL. 6, 2002, Pages

  Chan, S ^a  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARZOXIFENE; TAMOXIFEN;

ARTICLE; BREAST CARCINOMA; CANCER PATIENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0036754189     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0959-8049(02)00286-1     Document Type: Article

References (4)

1. Vernon M.W. Experimental endometriosis in laboratory animals as a research model. Prog Clin Biol Res. 323:1990;49-60.
2. Thigpen J.T., Brady M.F., Alvarez R.D.et al. Oral medroxyprogesterone acetate in the treament of advanced or recurrent endometrial carcinoma. a dose-response study by the Gynecologic Oncology Group J Clin Oncol. 17:1999;1736-1744.
3. Thigpen J.T., Brady M.F., Howard D.et al. Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: A Gynaecological Oncology Group Study. J. Clin Oncol. 19:2001;364-367.
4. Buzdar AU, Shaughnessy J, Hudis C, et al. Preliminary results of a randomized double-blind phase 2 study of the selective estrogen receptor modulator (SERM) Arzoxifene in patients with locally advanced or metastatic breast cancer. Proceedings of ASCO 2001 20 (abstr 178).